Eur J Neurol. 2021 Mar 17. doi: 10.1111/ene.14828. Online ahead of print.
ABSTRACT
BACKGROUND: Monoclonal antibodies targeting CGRP or its receptor (anti-CGRP mAbs) are proven to be effective treatments in migraine prevention. Real-world evidence studies assessing their efficacy are scarce.
METHODS: Our objective was to assess the efficacy of anti-CGRP mAbs in our clinical cohort resistant to onabotulinumtoxinA. We prospectively analyzed ≥50% response rate in patients who initiated treatment with anti-CGRP mAbs and who were partial or non-responders to onabotulinumtoxinA.
RESULTS: 155 patients completed treatment with anti-CGRP mAbs at 3-month of follow-up. No statistically significant differences were found in ≥50% response in headache frequency in patients with prior onabotulimuntoxinA treatment partial or complete failure. Regarding dual therapy with onabotulinumtoxinA and anti-CGRP mAbs, no statistically significant differences were found in ≥50% response in headache frequency between monotherapy or dual therapy.
CONCLUSIONS: Patients with prior treatment failure or partial efficacy to onabotulinumtoxinA respond to anti-CGRP mAbs. After 3 months, in our cohort, dual therapy does not seem to add more benefit than anti-CGRP mAbs in monotherapy.
PMID:33730441 | DOI:10.1111/ene.14828
